₹37.95 Crores | Listing at BSE | Fri, Aug 5, 2022 - Fri, Aug 19, 2022
Gennex Laboratories Limited Rights Issue comprises 6.33 Cr equity shares aggregating to ₹37.95 Cr, offered at an issue price of ₹6 per share with a face value of ₹1 per share.
The record date for determining eligible shareholders is Jul 22, 2022.
As per the terms of payment, ₹6 per share payable on application, with the balance payable in call(s).
The Rights Entitlements are expected to be credited to eligible demat accounts on Aug 4, 2022.
The Rights Issue opens on Aug 5, 2022, and closes on Aug 19, 2022, with renunciation of Rights Entitlements permitted up to Aug 12, 2022.
The deemed date of allotment is Aug 26, 2022, following which the equity shares are expected to be credited to demat accounts on Aug 31, 2022 and listed on the BSE on Sep 2, 2022.
Bigshare Services Pvt.Ltd. is the Registrar to the Issue.
Investors are advised to refer to the Gennex Laboratories Limited Letter of Offer for detailed information, including risk factors, issue terms, and procedural details.
Record Date
Fri, Jul 22, 2022
Entitlement Ratio
:
Open Date
Fri, Aug 5, 2022
Close Date
Fri, Aug 19, 2022
| Period Ended | Total Assets | Total Revenue | Profit After Tax |
|---|---|---|---|
| 31-Mar-21 | 59.08 | 60.17 | 4.04 |
| 31-Mar-22 | 68.21 | 62.6 | 3.92 |
| Amount in ₹ Crore | |||
Incorporated in 1995, Gennex Laboratories Limited is a Manufacturer of Pharmaceutical Ingredients. The company manufactures products such as Guaifenesin, Methocarbamol, Fluconazole, Mephenesin, Phenazopyridine Hcl, Melitracen Hcl, Flupentixol Di-Hydrochloride, Chlorphenesin, Allopurinol, among other.
The company's unit is located in IDA Bollaram. Over 70% of the company's business comes from exports to over 50 countries across 5 continents.
Gennex Laboratories has a strong foothold in markets such as LATAM, MENA, SE Asia and the Indian Sub-Continent regions.
The Objects of the Issue are:
1. Meeting the Working capital requirement
2. Repayment of borrowings availed by the Company from lenders.
3. Further Investment in Deccan Remedies Ltd.,
4. General Corporate Purposes.
[Dilip Davda] Despite over 97% capacity utilization, it has posted an average financial performance indicating higher competition and pressure on margins. Considering the current market price, which appears to have been maintained above RI pricing to lure investors, risk seeker/cash surplus investors may consider parking funds for the long term. Read detail review...
Gennex Laboratories Limited
'Akash Ganga' 3rd Floor,
Plot No.144, Srinagar Colony,
Hyderabad-500073, T.S
Hyderabad, Telangana, 500073
The Gennex Laboratories Rights Issue 2022 opens on Fri, Aug 5, 2022, and closes on Fri, Aug 19, 2022.
Gennex Laboratories Rights Issue 2022 Schedule
| Last Date for credit of Rights Entitlements | Thu, Aug 4, 2022 |
| Last Date for renunciation of Rights Entitlements | Fri, Aug 12, 2022 |
| Issue Opening Date | Fri, Aug 5, 2022 |
| Issue Closing Date | Fri, Aug 19, 2022 |
| Date of Allotment (on or about) | Fri, Aug 26, 2022 |
| Date of Credit (on or about) | Wed, Aug 31, 2022 |
| Date of Listing (on or about) | Fri, Sep 2, 2022 |
You can apply for Gennex Laboratories Rights Issue 2022 in two ways:
Steps to apply for Gennex Laboratories Rights Issue 2022 using Net Banking (ASBA)
Steps to apply for Gennex Laboratories Rights Issue 2022 using Registrar's website (R-WAP)
